Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 4/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580887 | 0.89 | AOC1 (0.41) | AOC1PRKCQPRKCDROCK2ROCK1 | |
| SCHEMBL1034426 | 0.89 | ROCK2 (0.47) | AOC1PRKCQPRKCDROCK2ROCK1 | |
| SCHEMBL19520790 | 0.79 | AOC1 (0.57) | AOC1PTGS1PTGS2AOC3MEN1 | |
| Hydrochloric Acid SCHEMBL3978097 | 0.76 | AOC1 (0.48) | AOC1ROCK2ROCK1PTGS1PTGS2 | |
| SCHEMBL24074639 | 0.74 | KMT2A (0.47) | PRKCQMEN1KMT2A | |
| SCHEMBL30751786 | 0.74 | ROCK2 (0.51) | AOC1ROCK2ROCK1AOC3MEN1 | |
| SCHEMBL1920863 | 0.74 | ROCK2 (0.51) | AOC1ROCK2ROCK1AOC3MEN1 | |
| SCHEMBL29539060 | 0.73 | AOC1 (0.54) | AOC1ROCK2ROCK1PTGS1PTGS2 | |
| SCHEMBL5958407 | 0.73 | AOC1 (0.54) | AOC1ROCK2ROCK1PTGS1PTGS2 | |
| SCHEMBL30041145 | 0.72 | CHRNB2 (0.36) | PRKCQPRKCDIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663285-B1 | FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD (CN) | 2022-04-26 | — | — | US | disclosed |
| EP-2099796-B1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2099796-B1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2099796-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312701-B2 | Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof | FGFR4, FGFR1, FGFR2 | AOC1 4467/4885PRKCQ 2418/4885PRKCD 2106/4885 |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | AOC1 1424/4885PRKCQ 541/4885PRKCD 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.